Quarterly report · Q2
4578.TEDINET S100RHW0
Period2023-01-01 → 2023-06-30
Filed2023-07-31
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥947.5bn | 2023-01-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥499.2bn | 2023-04-01 → 2023-06-30d | Cons. | Revenue IFRS |
| Revenue | ¥1.74T | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥814.3bn | 2022-01-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥434.0bn | 2022-04-01 → 2022-06-30d | Cons. | Revenue IFRS |
| Operating income | ¥130.7bn | 2023-01-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥53.9bn | 2023-04-01 → 2023-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥67.1bn | 2022-01-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥46.4bn | 2022-04-01 → 2022-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥138.8bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥59.6bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥173.0bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥92.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥61.8bn | 2022-04-01 → 2022-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥102.6bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥41.2bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥133.9bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥69.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥46.5bn | 2022-04-01 → 2022-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥105.1bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥42.4bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss IFRS |
| Net income | ¥71.5bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥47.3bn | 2022-04-01 → 2022-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥3.31T | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥3.10T | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.10T | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥840.3bn | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥840.3bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.47T | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.26T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.26T | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.05T | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥2.43T | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.23T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.23T | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥498.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥471.6bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥456.8bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥410.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥113.5bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥211.8bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥118.8bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥54.3bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥81.6bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥56.0bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥46.8bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥95.5bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥48.2bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥189.06 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥75.85 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥246.8 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥128.61 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥85.74 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥189.06 | 2023-01-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥75.85 | 2023-04-01 → 2023-06-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥246.78 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥128.57 | 2022-01-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥85.69 | 2022-04-01 → 2022-06-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 73.4% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.8% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-06-30 | ¥87.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-06-30 | ¥44.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-06-30 | ¥66.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-06-30 | ¥33.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥21.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥11.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-06-30 | ¥7.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-06-30 | ¥4.0bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-06-30 | −¥21.1bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥11.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-06-30 | −¥21.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥11.5bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥25.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥12.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥9.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥9.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥9m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥4m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥8.0bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥5.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥226.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥122.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥226.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥122.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥54m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥40m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥6.7bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥4.5bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥637.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥334.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥637.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥334.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥133.6bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥61.0bn |
| —segment total | revenue | 2023-01-01 → 2023-06-30 | ¥968.7bn |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥510.7bn |
| —segment total | revenue external | 2023-01-01 → 2023-06-30 | ¥947.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥499.2bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥21.1bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥11.5bn |
| —segment total | segment profit | 2023-01-01 → 2023-06-30 | ¥156.0bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥66.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-01-01 → 2022-06-30 | ¥82.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥43.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-01-01 → 2022-06-30 | ¥62.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥32.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥20.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥11.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-06-30 | ¥7.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | ¥3.8bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-06-30 | −¥20.1bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥11.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-06-30 | −¥20.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥11.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥22.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥11.1bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥16.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥9.0bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥16.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥9.0bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥5m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥2m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥1.8bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥205.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥115.4bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥205.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥115.4bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥11m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥7m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥28.1bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥16.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥529.3bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥277.2bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥529.3bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥277.2bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥52.2bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥34.9bn |
| —segment total | revenue | 2022-01-01 → 2022-06-30 | ¥834.4bn |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥445.3bn |
| —segment total | revenue external | 2022-01-01 → 2022-06-30 | ¥814.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥434.0bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥20.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥11.3bn |
| —segment total | segment profit | 2022-01-01 → 2022-06-30 | ¥90.0bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥57.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 894
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from long term borrowings fin cf IFRS | CurrentYTDDuration | 11000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -12870000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -8285000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -9610000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -10111000000 | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -28288000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -28450000000 | JPY |
| Capital contribution from non controlling interests fin cf IFRS | Prior1YTDDuration | － | JPY |
| Capital contribution from non controlling interests fin cf IFRS | CurrentYTDDuration | 2021000000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | Prior1YTDDuration | － | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | CurrentYTDDuration | -1980000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -48217000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -46752000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | Prior1YTDDuration | 14577000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | CurrentYTDDuration | 12446000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 410684000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 471634000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 31497000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 14578000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 456759000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 498659000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 529294000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 205759000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 16663000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 62589000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 814307000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 814307000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 11000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 5000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 20078000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 20095000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -20095000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration | － | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 529294000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 205770000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 16669000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 82668000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 834403000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -20095000000 | JPY |
| Revenue IFRS | Prior1YTDDuration | 814307000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 52194000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 28132000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 1750000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 7873000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 89950000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -22804000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 67146000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 637853000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |